NRX Pharmaceuticals Inc has a consensus price target of $22.5 based on the ratings of 5 analysis. The 3 most-recent analyst ratings were released by Ascendiant Capital, HC Wainwright & Co., and HC Wainwright & Co. on June 7, 2024, May 25, 2023, and February 2, 2023, respectively. With an average price target of $15.67 between Ascendiant Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 529.18% upside for NRX Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/07/2024 | Buy Now | 1626.91% | Ascendiant Capital | Edward Woo | $50 → $43 | Maintains | Buy | Get Alert |
05/25/2023 | Buy Now | -19.68% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Reiterates | Buy → Buy | Get Alert |
02/02/2023 | Buy Now | -19.68% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Reiterates | → Buy | Get Alert |
11/09/2022 | Buy Now | 60.64% | Ascendiant Capital | Edward Woo | → $40 | Initiates | → Buy | Get Alert |
06/30/2022 | Buy Now | -19.68% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Initiates | → Buy | Get Alert |
The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by Ascendiant Capital on June 7, 2024. The analyst firm set a price target for $43.00 expecting NRXP to rise to within 12 months (a possible 1626.91% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for NRX Pharmaceuticals (NASDAQ:NRXP) was provided by Ascendiant Capital, and NRX Pharmaceuticals maintained their buy rating.
There is no last upgrade for NRX Pharmaceuticals
There is no last downgrade for NRX Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a maintained with a price target of $50.00 to $43.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $2.49, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.